Tempus Acquires Highline Sciences

Tempus has announced the acquisition of Highline Sciences, a ​​CRO focused on oncology.

Highline Sciences manages and executes on early and late-stage clinical trials. Highline’s capabilities will help support and grow new and established business lines within Tempus, allowing the company to vertically integrate more clinical trial services when appropriate to complement its existing CRO partnerships.

Read more about this new partnership here.